Hereditary thyroid cancer syndromes and genetic testing

Journal of Surgical Oncology

Volumn 111, Issue 1, 2015, Pages 51-60

  Rowland, Kathryn J ^a   Moley, Jeffrey F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hereditary thyroid cancer; Medullary thyroid cancer; Multiple endocrine neoplasia; Nonmedullary thyroid cancer; Ret proto oncogene

Indexed keywords

CANCER GENETICS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CARNEY COMPLEX; CLINICAL FEATURE; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; GENETIC SCREENING; HEREDITARY MEDULLARY THYROID CANCER; HEREDITARY NONMEDULLARY THYROID CANCER; HUMAN; LONG TERM SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; REVIEW; SURGICAL APPROACH; SYSTEMIC THERAPY; THYROID CANCER; WERNER SYNDROME; GENETICS; NEOPLASTIC SYNDROMES, HEREDITARY; THYROID NEOPLASMS;

GENETIC TESTING; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; THYROID NEOPLASMS;

EID: 84920048520     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23769     Document Type: Review

References (128)

1. Davidson HC, Park BJ, Johnson JT: Papillary thyroid cancer: Controversies in the management of neck metastasis. Laryngoscope 2008;118:2161-2165.
2. Pellegriti G, Frasca F, Regalbuto C, et al: Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212.
3. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
4. Jemal A, Siegel R, Xu J, et al.: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
5. Bergholm U, Adami HO, Bergstrom R, et al.: Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group. Acta Chir Scand 1990;156:37-46.
6. Hundahl SA, Fleming ID, Fremgen AM, et al.: A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns. Cancer 1998;83:2638-2648.
7. Kebebew E, Ituarte PH, Siperstein AE, et al.: Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-1148.
8. Eng C, Clayton D, Schuffenecker I, et al.: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276:1575-1579.
9. Eng C, Mulligan LM, Smith DP, et al.: Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 1995;12:209-212.
10. Howe JR, Norton JA, Wells SA Jr: Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: Results of long-term follow-up. Surgery 1993;114:1070-1077.
11. Machens A, Holzhausen HJ, Thanh PN, et al.: Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 2003;134:425-431.
12. Mulligan LM, Eng C, Healey CS, et al.: Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994;6:70-74.
13. Machens A, Niccoli-Sire P, Hoegel J, et al.: Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-1525.
14. Brandi ML, Gagel RF, Angeli A, et al.: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinolo Metab 2001;86:5658-5671.
15. Kloos RT, Eng C, Evans DB, et al.: Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
16. Tran T, Gianoukakis AG: Familial thyroid neoplasia: Impact of technological advances on detection and monitoring. Curr Opin Endocrinol Diabetes Obes 2010;17:425-431.
17. Moley JF, DeBenedetti MK: Patterns of nodal metastases in palpable medullary thyroid carcinoma: Recommendations for extent of node dissection. Ann Surg 1999;229:880-887;discussion 887-888.
18. Machens A, Dralle H: Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2655-2663.
19. Lips CJ, Landsvater RM, Hoppener JW, et al.: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Eng J Med 1994;331:828-835.
20. Rowland KJ, Chernock RD, Moley JF: Pheochromocytoma in an 8-year-old patient with multiple endocrine neoplasia type 2A: Implications for screening J Surg Oncol 2013;108:203-206.
21. Kouvaraki MA, Shapiro SE, Fornage BD, et al.: Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134:946-954;discussion 954-955.
22. Machens A, Schneyer U, Holzhausen HJ, et al.: Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005;90:2029-2034.
23. Dralle H, Damm I, Scheumann GF, et al.: Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994;24:112-121.
24. Carty SE, Cooper DS, Doherty GM, et al.: Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009;19:1153-1158.
25. Moley JF, Wells SA: Compartment-mediated dissection for papillary thyroid cancer. Langenbecks Arch Surg 1999;384:9-15.
26. Fleming JB, Lee JE, Bouvet M, et al.: Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999; 230:697-707.
27. Machens A, Hauptmann S, Dralle H: Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 2008;95:586-591.
28. Machens A, Holzhausen HJ, Dralle H: Prediction of mediastinal lymph node metastasis in medullary thyroid carcinoma. Br J Surg 2004;91:709-712.
29. Skinner MA, DeBenedetti MK, Moley JF, et al.: Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B J Pediatr Surg 1996;31:177-181;discussion 181-182.
30. Guillem JG, Wood WC, Moley JF, et al.: ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006;24:4642-4660.
31. Guillem JG, Wood WC, Moley JF, et al.: ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol 2006;13:1296-1321.
32. Skinner MA, Moley JA, Dilley WG, et al.: Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A New Eng J Med 2005;353:1105-1113.
33. Clark JR, Fridman TR, Odell MJ, et al.: Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 2005;115: 1445-1450.
34. Moley JF, Fialkowski EA: Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 2007;31:946-956.
35. van Heerden JA, Grant CS, Gharib H, et al.: Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990;212:395-400;discussion 400-401.
36. Laure Giraudet A, Al Ghulzan A, Auperin A, et al.: Progression of medullary thyroid carcinoma: Assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008;158:239-246.
37. Giraudet AL, Vanel D, Leboulleux S, et al.: Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007;92:4185-4190.
38. Jackson CE, Norum RA, Talpos GB, et al.: Clinical value of calcitonin and carcinoembryonic antigen doubling times in medullary thyroid carcinoma. Henry Ford Hosp Med J 1987;35:120-121.
39. Meijer JA, le Cessie S, van den Hout WB, et al.: Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: A structured meta-analysis. Clin Endocrin (Oxf) 2010;72:534-542.
40. RendlG, ManzlM, HitzlW, et al.:Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2008;69:497-505.
41. Dottorini ME, Assi A, Sironi M, et al.: Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996;77:1556-1565.
42. Schreinemakers JM, Vriens MR, Valk GD, et al.: Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: A nationwide long-term follow-up study. World J Surg 2010;34:852-860.
43. Ellenhorn JD, Shah JP, BrennanMF: Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 1993;114:1078-1081;discussion 1081-1082.
44. Fialkowski E, DeBenedetti M, Moley J: Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 2008;32:754-765.
45. Gimm O, Dralle H: Reoperation in metastasizing medullary thyroid carcinoma: Is a tumor stage-oriented approach justified? Surgery 1997;122:1124-1130;discussion 1130-1131.
46. GimmO, Ukkat J, DralleH:Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 1998;22:562-567;discussion 567-568.
47. Tisell LE, Hansson G, Jansson S, et al.: Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986;99:60-66.
48. Tung WS, Vesely TM, Moley JF: Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995;118:1024-1029;discussion 1029-1030.
49. Moley JF, Lairmore TC, Doherty GM, et al.: Preservation of the recurrent laryngeal nerves in thyroid and parathyroid reoperations. Surgery 1999;126:673-677;discussion 677-679.
50. FaikErdogan M, Gursoy A, Erdogan G, et al.: Radioactive iodine treatment in medullary thyroid carcinoma. Nucl Med Commun 2006;27:359-362.
51. Brierley J, Tsang R, Simpson WJ, et al.: Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-310.
52. Brierley JD, Tsang RW: External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clin North Am 1996; 25:141-157.
53. Carlomagno F, Guida T, Anaganti S, et al.: Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23:6056-6063.
54. Carlomagno F, Vitagliano D, Guida T, et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.
55. Wells SA Jr, Gosnell JE, Gagel RF, et al.: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-772.
56. Robinson BG, Paz-Ares L, Krebs A, et al.: Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2664-2671.
57. Wells SA Jr, Robinson BG, Gagel RF, et al.: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 2012;30:134-141.
58. Kurzrock R, Sherman SI, Ball DW, et al.: Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clinical Oncol 2011;29:2660-2666.
59. Lam ET, Ringel MD, Kloos RT, et al.: Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323-2330.
60. Chow LQ, Eckhardt SG: Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007;25:884-896.
61. Cleary JM, Sadow PM, Randolph GW, et al.: Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol 2010;28:e390-e392.
62. Schlumberger MJ, Elisei R, Bastholt L, et al.: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-3801.
63. Stein R, Goldenberg DM: A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 2004;3:1559-1564.
64. Caron NR, Clark OH: Papillary thyroid cancer. Curr Treat Options Oncol 2006;7:309-319.
65. Kondo T, Ezzat S, Asa SL: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
66. Kebebew E: Hereditary non-medullary thyroid cancer. World J Surg 2008;32:678-682.
67. Nose V: Thyroid cancer of follicular cell origin in inherited tumor syndromes. Adv Anat Pathol 2010;17:428-436.
68. Cetta F, Montalto G, Gori M, et al.: Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: Results from a European cooperative study. J Clin Endocrinol Metab 2000;85:286-292.
69. Mazeh H, Sippel RS: Familial nonmedullary thyroid carcinoma. Thyroid 2013;23:1049-1056.
70. Herraiz M, Barbesino G, Faquin W, et al.: Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 2007;5:367-373.
71. Jarrar AM, Milas M, Mitchell J, et al.: Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 2011;253:515-521.
72. Steinhagen E, Guillem JG, Chang G, et al.: The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clinical colorectal cancer 2012;11:304-308.
73. Powell SM, Petersen GM, Krush AJ, et al.: Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993;329:1982-1987.
74. Petersen GM, Francomano C, Kinzler K, et al.: Presymptomatic direct detection of adenomatous polyposis coli (APC) gene mutations in familial adenomatous polyposis. Hum Genet 1993; 91:307-311.
75. Liaw D, Marsh DJ, Li J, et al.: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-67.
76. Marsh DJ, Coulon V, Lunetta KL, et al.: Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan- Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7:507-515.
77. Zhou XP, Waite KA, Pilarski R, et al.: Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. American journal of human genetics 2003;73:404-411.
78. Metzger R, Milas M: Inherited cancer syndromes and the thyroid: an update. Curr Opin Oncol 2014;26:51-61.
79. Pan L, Peng L, Jean-Gilles J, et al.: Novel PRKAR1A gene mutations in Carney Complex. Int J Clin Exp Pathol 2010;3:545-548.
80. Stratakis CA, Courcoutsakis NA, Abati A, et al.: Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab 1997;82:2037-2043.
81. Horvath A, Bertherat J, Groussin L, et al.: Mutations and polymorphisms in the gene encoding regulatory subunit type 1- alpha of protein kinase A (PRKAR1A): An update. Hum Mutat 2010;31:369-379.
82. Salpea P, Horvath A, London E, et al.: Deletions of the PRKAR1A locus at 17q24.2-q24.3 in Carney complex: Genotype-phenotype correlations and implications for genetic testing. J Clin Endocrinol Metab 2014;99:E183-E188.
83. Ishikawa Y, Sugano H, Matsumoto T, et al.: Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race. Cancer 1999;85:1345-1352.
84. Huang S, Lee L, Hanson NB, et al.: The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat 2006;27:558-567.
85. Sippel RS, Caron NR, Clark OH: An evidence-based approach to familial nonmedullary thyroid cancer: Screening, clinical management, and follow-up. World J surg 2007;31:924-933.
86. Hemminki K, Dong C: Familial relationships in thyroid cancer by histo-pathological type. Int J Cancer 2000;85:201-205.
87. Pal T, Vogl FD, Chappuis PO, et al.: Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: A hospital-based study. J Clin Endocrinol Metab 2001;86:5307-5312.
88. Ron E, Kleinerman RA, LiVolsi VA, et al.: Familial nonmedullary thyroid cancer. Oncology 1991;48:309-311.
89. Moses W, Weng J, Kebebew E: Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid 2011;21:367-371.
90. Charkes ND: On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid 2006;16:181-186.
91. Bevan S, Pal T, Greenberg CR, et al.: A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: Confirmation of linkage to TCO1. J Clin Endocrinol Metab 2001;86:3701-3704.
92. Bignell GR, Canzian F, Shayeghi M, et al.: Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997;61:1123-1130.
93. Cantara S, Pisu M, Frau DV, et al.: Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer. J Clin Endocrinol Metab 2012;97:E1327-1331.
94. Canzian F, Amati P, Harach HR, et al.: A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 1998;63:1743-1748.
95. Capezzone M, Cantara S, Marchisotta S, et al.: Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. J Clin Endocrinol Metab 2008;93:3950-3957.
96. Cavaco BM, Batista PF, Martins C, et al.: Familial nonmedullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Endocr Relat Cancer 2008;15:207-215.
97. He M, Bian B, Gesuwan K, et al.: Telomere length is shorter in affected members of families with familial nonmedullary thyroid cancer. Thyroid 2013;23:301-307.
98. Malchoff CD, Sarfarazi M, Tendler B, et al.: Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000;85:1758-1764.
99. McKay JD, Lesueur F, Jonard L, et al.: Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001;69:440-446.
100. McKay JD, Thompson D, Lesueur F, et al.: Evidence for interaction between the TCO and NMTC1 loci in familial nonmedullary thyroid cancer. J Med Genet 2004;41:407-412.
101. Neumann S, Willgerodt H, Ackermann F, et al.: Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na+/I- symporter. J Clin Endocrinol Metab 1999; 84:3750-3756.
102. Prazeres HJ, Rodrigues F, Soares P, et al.: Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of nonmedullary thyroid carcinoma. Fam Cancer 2008;7:141-149.
103. Tomaz RA, Sousa I, Silva JG, et al.: FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility. Clin Endocrinol (Oxf) 2012;77:926-933.
104. Khan A, Smellie J, Nutting C, et al.: Familial nonmedullary thyroid cancer: A review of the genetics. Thyroid 2010;20:795-801.
105. Stankov K, Pastore A, Toschi L, et al.: Allelic loss on chromosomes 2q21 and 19p 13.2 in oxyphilic thyroid tumors. Int J Cancer 2004;111:463-467.
106. Jendrzejewski J, Tomsic J, Lozanski G, et al.: Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2011;96: E1876-1880.
107. Weber F, Eng C: Update on the molecular diagnosis of endocrine tumors: Toward -omics-based personalized healthcare? J Clin Endocrinol Metab 2008;93:1097-1104.
108. Sturgis EM, Li G: Molecular epidemiology of papillary thyroid cancer: In search of common genetic associations. Thyroid 2009;19:1031-1034.
109. Landa I, Boullosa C, Inglada-Perez L, et al.: An epistatic interaction between the PAX8 and STK17B genes in papillary thyroid cancer susceptibility. PloS one 2013;8:e74765.
110. Malchoff CD, Malchoff DM: Familial nonmedullary thyroid carcinoma. Cancer control 2006;13:106-110.
111. Loh KC: Familial nonmedullary thyroid carcinoma: A metareview of case series. Thyroid 1997;7:107-113.
112. Alsanea O, Wada N, Ain K, et al.: Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series. Surgery 2000;128:1043-1050;discussion 1050-1051.
113. Hillenbrand A, Varhaug JE, Brauckhoff M, et al.: Familial nonmedullary thyroid carcinoma-clinical relevance and prognosis. A European multicenter study. ESES Vienna presentation. Langenbecks Arch Surg 2010;395:851-858.
114. Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, et al.: Clinical characteristics and outcome of familial nonmedullary thyroid cancer: A retrospective controlled study. Thyroid 2011;21: 43-48.
115. Uchino S, Noguchi S, Kawamoto H, et al.: Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg 2002;26:897-902.
116. Maxwell EL, Hall FT, Freeman JL: Familial non-medullary thyroid cancer: A matched-case control study. Laryngoscope 2004;114:2182-2186.
117. Mazeh H, Benavidez J, Poehls JL, et al.: In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid 2012;22:3-8.
118. Park YJ, Ahn HY, Choi HS, et al.: The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases. Thyroid 2012;22:356-362.
119. Ito Y, Kakudo K, Hirokawa M, et al.: Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery 2009;145:100-105.
120. Vriens MR, Sabanci U, Epstein HD, et al.: Reliability of fineneedle aspiration in patients with familial nonmedullary thyroid cancer. Thyroid 1999;9:1011-1016.
121. Uchino S, Noguchi S, Yamashita H, et al.: Detection of asymptomatic differentiated thyroid carcinoma by neck ultrasonographic screening for familial nonmedullary thyroid carcinoma. World J Surg 2004;28:1099-1102.
122. Sadowski SM, He M, Gesuwan K, et al.: Prospective screening in familial nonmedullary thyroid cancer. Surgery 2013;154:1194-1198.
123. Tomoda C, Miyauchi A, Uruno T, et al.: Cribriform-morular variant of papillary thyroid carcinoma: Clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 2004;28:886-889.
124. Milas M, Mester J, Metzger R, et al.: Should patients with Cowden syndrome undergo prophylactic thyroidectomy? Surgery 2012; 152:1201-1210.
125. Tan MH, Mester JL, Ngeow J, et al.: Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012;18:400-407.
126. Bubien V, Bonnet F, Brouste V, et al.: High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet 2013;50:255-263.
127. Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 2011;96:E2063-2071.
128. Salpea P, Stratakis CA: Carney complex and McCune Albright syndrome: An overview of clinical manifestations and human molecular genetics. Mol Cell Endocrinol 2014;386:85-91.